Inclusion Criteria:

- Have histologically confirmed prostate cancer.

- Have completed primary therapy (radical prostatectomy, external beam radiation,
brachytherapy) for prostate cancer. "Watchful waiting" patients will also be
eligible.

- Have either two consecutive rises in prostate specific antigen (PSA) or a series of
at least four PSA's over two years where the PSA doubling time is at least 3 months
following a nadir response to localized therapy. The minimum PSA for this study is
0.2 ng/dL.

- Not be receiving ongoing chemotherapy, radiation therapy or biological therapy for
internal malignancy including prostate cancer.

- At time of entry, the clinical team expects that no additional interventions for
prostate cancer therapy (hormonal, chemotherapy, radiotherapy, etc.) will be
necessary over the next 5 months.

- Not be currently using Finasteride, androgens, or other PSA modifying hormonal
agents. Utilizing prescription medications for urinary outlet obstructive symptoms
will not be permitted. The use of non-prescription substances to improve urinary
tract symptoms will not be permitted (i.e. Saw Palmetto, other herbal, alternative
products).

- Have kidney and liver enzymes within normal limits. Men with kidney and liver enzymes
that are slightly elevated (< 1.5 times the upper normal limit), but have been stable
for several months particularly those that are related to a known disorder (such as
Gilberts syndrome, past history of alcohol, hepatitis, or a history of non-alcoholic
steatohepatitis) will be permitted to participate after clinical evaluation by the
study physician."

- Have no history of malabsorptive disorders or other metabolic disorders requiring
special diet recommendations. Diabetics will be permitted to participate.

- Voluntarily agree to participate and a sign an informed consent document.

- Agree to consume a standardized vitamin and mineral supplement and avoid other
nutrition, dietary, or alternative medications/supplements for the duration of the
study.

Exclusion Criteria:

- Have an active malignancy other than prostate cancer that requires therapy.

- Have a history of pituitary hormone diseases that currently require supplemental
hormonal administration (thyroid hormones, adrenocorticotropic hormone, growth
hormone) or other endocrine disorders requiring hormone administration with the
exception of diabetes, osteoporosis and men who have been stable (> 6 months of
thyroid stimulating hormone within normal limits) on thyroid replacement therapy.

- Have a known allergy to tree nuts, soy or wheat protein.

- Have a recent history of iron deficient anemia (possible accentuation by soy).

- Antibiotic use in the last 6 months.